Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Financials | Market Cap | ROE | ROA | ROCE | ROIC | D/E | Current Ratio | Gross Margin | Profit Margin | Operating Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLNO | SOLENO THERAPEUTICS INC | $1.73B | 5.80% | 4.50% | 5.25% | 7.60% | 0.25 | 5.80 | 98.60% | 10.80% | 13.85% | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $43.88B | 90.30% | 6.70% | 16.45% | 11.30% | 5.29 | 2.76 | 81.60% | 8.40% | 15.50% | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $547.19M | 74.60% | 33.80% | 38.56% | 47.10% | 0.84 | 5.68 | 84.50% | 78.20% | 88.90% | ||
| ADMA | ADMA BIOLOGICS INC | $2.15B | 35.00% | 26.00% | 34.21% | 38.40% | 0.31 | 6.71 | 57.40% | 28.80% | 37.20% | ||
| CORT | CORCEPT THERAPEUTICS INC | $4.29B | 15.10% | 11.90% | 6.46% | 7.60% | 0.29 | 2.92 | 98.30% | 12.90% | 5.69% | ||
| ABEO | ABEONA THERAPEUTICS INC | $255.58M | 53.20% | 35.80% | 39.49% | 67.10% | 0.38 | 6.93 | 73.70% | 1,223.10% | 1,289.05% | ||
| HALO | HALOZYME THERAPEUTICS INC | $7.63B | 92.70% | 14.10% | 20.65% | 20.10% | 50.73 | 4.66 | 83.60% | 22.70% | 34.73% | ||
| KRYS | KRYSTAL BIOTECH INC | $7.55B | 18.70% | 17.10% | 15.39% | 26.00% | 0.09 | 9.95 | 94.10% | 52.60% | 48.69% | ||
| NAGE | NIAGEN BIOSCIENCE INC | $353.15M | 26.10% | 18.40% | 21.03% | 138.30% | 0.39 | 4.86 | 64.30% | 13.40% | 14.06% | ||
| RPRX | ROYALTY PHARMA PLC | $27.67B | 8.00% | 4.10% | 5.68% | 4.40% | 1.02 | 2.40 | 100.00% | 32.40% | 45.35% | ||
| VCEL | VERICEL CORP | $1.63B | 5.20% | 3.70% | 4.10% | 4.40% | 0.38 | 5.03 | 74.40% | 6.00% | 6.52% | ||
| APLS | APELLIS PHARMACEUTICALS INC | $5.14B | 8.20% | 2.40% | 9.10% | 9.20% | 1.91 | 3.14 | 89.80% | 2.20% | 6.82% | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $1.62B | 19.80% | 13.70% | 22.53% | 55.20% | 0.46 | 3.60 | 77.20% | 18.30% | 26.45% | ||
| MNKD | MANNKIND CORP | $754.85M | -11.20% | 1.10% | 6.35% | 6.50% | -16.53 | 1.71 | 74.80% | 1.70% | 11.30% | ||
| TECH | BIO-TECHNE CORP | $8.18B | 4.10% | 3.20% | 5.15% | 9.40% | 0.25 | 4.54 | 65.20% | 6.70% | 10.09% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $10.86B | 5.80% | 4.70% | 7.22% | 8.70% | 0.25 | 5.21 | 77.70% | 10.80% | 15.32% | ||
| EXEL | EXELIXIS INC | $11.14B | 36.90% | 28.00% | 38.59% | 42.20% | 0.32 | 3.56 | 96.40% | 33.70% | 40.57% | ||
| VCYT | VERACYTE INC | $2.56B | 5.30% | 4.90% | 5.07% | 34.00% | 0.07 | 8.15 | 70.10% | 12.80% | 13.19% | ||
| XOMA | XOMA ROYALTY CORP | $373.48M | 22.50% | 7.60% | 13.31% | 14.80% | 2.01 | 3.37 | 100.00% | 35.50% | 60.69% | ||
| REGN | REGENERON PHARMACEUTICALS INC | $81.68B | 14.80% | 11.50% | 14.57% | 15.60% | 0.30 | 4.13 | 85.40% | 31.40% | 36.77% | ||
| CPRX | CATALYST PHARMACEUTICALS INC | $3.02B | 24.30% | 21.20% | 29.63% | 308.40% | 0.16 | 6.08 | 85.20% | 36.40% | 48.14% | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $113.44B | 22.70% | 16.20% | 21.38% | 29.90% | 0.37 | 2.90 | 86.20% | 32.90% | 38.80% | ||
| LGND | LIGAND PHARMACEUTICALS INC | $3.98B | 13.90% | 10.20% | 10.75% | 17.20% | 0.53 | 22.23 | 94.60% | 46.40% | 61.05% | ||
| UTHR | UNITED THERAPEUTICS CORP | $25.99B | 19.30% | 17.30% | 23.68% | 31.70% | 0.11 | 6.61 | 87.90% | 41.90% | 54.46% | ||
| INCY | INCYTE CORP | $18.73B | 29.10% | 20.70% | 30.63% | 77.30% | 0.35 | 3.32 | 92.80% | 25.00% | 32.42% | ||
| CRMD | CORMEDIX INC | $536.75M | 58.50% | 33.00% | 23.44% | 91.90% | 1.04 | 2.11 | 88.50% | 52.30% | 49.02% | ||
| MDXG | MIMEDX GROUP INC | $586.84M | 21.20% | 15.90% | 22.75% | 60.00% | 0.34 | 4.32 | 82.60% | 11.60% | 15.13% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.